Page results
-
UCLH and UCL are at the forefront of Women’s Health care and research – across areas including reproductive health, maternity, breast care, care for newborns, gynaecological care, and cancer.
-
Holistic Needs Assessment (HNA): Information for people affected by cancer and blood conditions patient information leaflet
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
This page has been written by the team in the mitochondrial clinic for patients who are seen at the National Hospital for Neurology and Neurosurgery, who have a diagnosis of mitochondrial disease. It outlines the importance of having your heart checked as part of your care.
-
The Royal National ENT Voice Centre is a national and international multidisciplinary centre for voice disorders. The voice clinic at the RNENT is one of the oldest in the UK.
File results
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer
-
FOI/2022/0194 - Drug treatment for lung cancer
-
FOI/2022/0199 - Trust postal service and patient communication
-
FOI/2022/0200 - IT budget/ chatbots